Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance
- 29 November 2006
- journal article
- review article
- Published by Informa UK Limited in Current Medical Research and Opinion
- Vol. 22 (12), 2603-2612
- https://doi.org/10.1185/030079906x154114
Abstract
Background: Resistance to antiretroviral (ARV) drugs constitutes one of the greatest limitations to effective long-term therapy for human immunodeficiency virus (HIV) infection – a problem alleviated, but by no means overcome, by the application of carefully selected, sequential combination regimens. The rational development of novel therapeutics with the ability to suppress viraemia effectively and also address the complex problems of resistance offers a useful way forward for HIV therapy. The investigational drug TMC114 (darunavir) was designed to be active against both wild-type HIV and strains that are resistant to currently available protease inhibitors. Scope: This review describes the challenges posed by HIV drug resistance and the novel approach taken in the design and selection of TMC114. Articles were identified by searching MEDLINE in September 2005 (search limits: 1995–2006) using the terms: TMC114, darunavir, resistance, screening, selection, ARV therapy, HIV and HAART. Additional data included bibliographies from identified articles. Findings: With the continuing problem of resistance, ARV drugs must be designed with broadspectrum activity forming a central part of their development and screening. Drugs must not only be able to treat existing resistant strains, but must also possess more intrinsic resilience to the development of resistance. TMC114 was designed and selected with strong emphasis on potent activity across a range of both wild-type and resistant HIV strains and high binding affinity to HIV protease. Conclusion: This review illustrates that future treatment strategies should include screening against multiple-resistant strains to optimize the identification of novel therapeutic agents for the treatment of HIV.Keywords
This publication has 40 references indexed in Scilit:
- Relationship between Adherence and the Development of Resistance in Antiretroviral‐Naive, HIV‐1–Infected Patients Receiving Lopinavir/Ritonavir or NelfinavirThe Journal of Infectious Diseases, 2005
- HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimensJournal of Clinical Laboratory Analysis, 2005
- Combating Susceptibility to Drug Resistance: Lessons from HIV-1 ProteaseCell Chemical Biology, 2004
- Transmission of HIV-1 drug resistanceJournal of Clinical Virology, 2004
- Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patientsAIDS, 2004
- Epidemiological aspects of transmitted HIV drug resistanceScandinavian Journal of Infectious Diseases, 2003
- Lopinavir/RitonavirDrugs, 2003
- Overcoming drug resistance in HIV‐1 chemotherapy: The binding thermodynamics of Amprenavir and TMC‐126 to wild‐type and drug‐resistant mutants of the HIV‐1 proteaseProtein Science, 2002
- HIV-1 evolution under pressure of protease inhibitors: Climbing the stairs of viral fitnessJournal of Biomedical Science, 1999
- Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical TrialsJournal of Biological Chemistry, 1996